Select ongoing clinical trials
| Type of therapy . | Clinical trial and design . | N of patients . | References . |
|---|---|---|---|
| Celoxicib vs placebo | Double-blind, randomized controlled trial aim: to test if celoxicib reduces the M protein concentration | 36 MGUS and SMM | Kalaycio 2004—ongoing |
| Lenalidomide vs observation | Open-label randomized controlled trial aim: to evaluate if lenalidomide extends TTP | 370* “High Risk” SMM | Lonial 2010—ongoing |
| Anti-KIR monoclonal antibody | Aim: to evaluate if anti-KIR reduces the M protein concentration >50% from baseline | 21 SMM | Landgren 2010—ongoing |
| BHQ880, a fully human, anti-Dickkopf1 (DKK1) neutralizing antibody | Single arm, open-label, phase 2 trial aim: to evaluate overall response rate | 58* “High Risk” SMM | Novartis Pharmaceuticals 2011—ongoing |
| Elotuzumab (humanized anti-CS1 monoclonal IgG1 antibody) | Aim: to assess the association between NK cell status and efficacy | 40* “High Risk” SMM | BMS Pharmaceuticals 2012—ongoing |
| Siltuximab (anti-IL-6 monoclonal antibody) | Randomized multicenter phase 2, blinded, placebo-controlled trial aim: 1-year PFS rate | 100* “High Risk” SMM | Janssen Pharmaceuticals 2012—ongoing |
| Carfilzomib, lenalidomide, and DEX | Single arm pilot (phase 2) trial aim: to evaluate overall response rate | 12 pilot + 18 expansion cohort (N=30) “High Risk” SMM | Landgren 2012—ongoing |
| Type of therapy . | Clinical trial and design . | N of patients . | References . |
|---|---|---|---|
| Celoxicib vs placebo | Double-blind, randomized controlled trial aim: to test if celoxicib reduces the M protein concentration | 36 MGUS and SMM | Kalaycio 2004—ongoing |
| Lenalidomide vs observation | Open-label randomized controlled trial aim: to evaluate if lenalidomide extends TTP | 370* “High Risk” SMM | Lonial 2010—ongoing |
| Anti-KIR monoclonal antibody | Aim: to evaluate if anti-KIR reduces the M protein concentration >50% from baseline | 21 SMM | Landgren 2010—ongoing |
| BHQ880, a fully human, anti-Dickkopf1 (DKK1) neutralizing antibody | Single arm, open-label, phase 2 trial aim: to evaluate overall response rate | 58* “High Risk” SMM | Novartis Pharmaceuticals 2011—ongoing |
| Elotuzumab (humanized anti-CS1 monoclonal IgG1 antibody) | Aim: to assess the association between NK cell status and efficacy | 40* “High Risk” SMM | BMS Pharmaceuticals 2012—ongoing |
| Siltuximab (anti-IL-6 monoclonal antibody) | Randomized multicenter phase 2, blinded, placebo-controlled trial aim: 1-year PFS rate | 100* “High Risk” SMM | Janssen Pharmaceuticals 2012—ongoing |
| Carfilzomib, lenalidomide, and DEX | Single arm pilot (phase 2) trial aim: to evaluate overall response rate | 12 pilot + 18 expansion cohort (N=30) “High Risk” SMM | Landgren 2012—ongoing |